Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men with characteristics of metabolic syndrome~   1. Waist circumference greater than 40 in (102 cm)~  2. Plasma TG greater than 150 mg/dL~  3. HDL cholesterol less than 40 mg/dL~  4. Blood pressure greater than or equal to 130/85 mmHg~  5. Fasting plasma glucose greater than 100 mg/dL but less than 126 mg/dL~  6. Fasting insulin great than 10 microunits/mL~2. 35-60 years of age~3. Overweight/obese subjects with BMI 27.1 - 35.0 kg/m2~4. Family history of cardiovascular disease or diabetes~5. Habitual diets containing ≥ 5.0% of energy from added sugars~6. Creatinine clearance of ≥80 mL/min~Exclusion Criteria:~1. Diagnosed cardiovascular disease (unstable angina, New York Heart Association angina \> Grade 2), abnormal thyroid function or liver/kidney disease, renal dysfunction (defined by a glomerular filtration rate \<80 mL/min)~2. Chronic skin disorder or treatment for acne~3. History of clinically significant dry eye or eye diseases such as glaucoma~4. Diabetes defined as fasting glucose ≥ 125 mg/dL or HbA1c ≥ 6.5%~5. Habitual diets with low content of added sugars (\<5% of total energy)~6. Any tobacco use~7. Elevated liver enzymes ≥ 3x normal (regional norms Alanine transaminase \<42 U/L, aspartate aminotransferase \<40 U/L, and gamma-glutamyl transferase 8-61 U/L)~8. Contraindications of MRI~9. Alcohol intake weekly greater than 56 g/week (4 standard drinks/wk).~10. Major surgery or donation of blood of \>500 mL within the past 8 wks.~11. Patients with uncontrolled hypertension, i.e. ≥160/95 mmHg.~12. Patients with known cardiac abnormalities.

- Gender: MALE
- Minimum Age: 35 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 3-V Bioscience-2640 (Type: EXPERIMENTAL): Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).